Literature DB >> 19495882

Evolving treatment strategies for gallbladder cancer.

Matthew T Hueman1, Charles M Vollmer, Timothy M Pawlik.   

Abstract

Gallbladder cancer is an uncommon cancer that has traditionally been associated with a poor prognosis. In the era of laparoscopic cholecystectomy, incidental gallbladder cancer has dramatically increased and now constitutes the major way patients present with gallbladder cancer. While patients with incidental gallbladder cancer have a better survival than patients with nonincidental gallbladder cancer, incidental gallbladder cancer can be associated with a varied prognosis. Imaging with computed tomography (CT), magnetic resonance imaging (MRI), and [18]F-fluorodeoxyglucose (FDG) positron emission tomography (PET), as well as diagnostic laparoscopy, all have varying roles in the workup of patients with incidental gallbladder cancer. For patients with T1b, T2, and T3 incidental gallbladder cancer re-resection is generally recommended. At re-exploration, many patients with incidental gallbladder cancer will have residual disease. Definitive oncologic management requires re-resection of the liver, portal lymphadenectomy, and attention to the common bile duct. The extent of the hepatic resection should be dictated by the ability to achieve a microscopically negative (R0) margin. Routine resection of the common bile duct is unnecessary but should be undertaken in the setting of a positive cystic duct margin. If an incidental gallbladder cancer is discovered at the time of surgery, whether the surgeon should directly proceed with a more definitive oncologic operation should depend on the surgeon's skill-set and experience. Gallbladder cancer has a propensity to recur. Although data for adjuvant therapy following resection are limited, some data do suggest a survival benefit for adjuvant chemoradiation therapy. Management of patients with gallbladder cancer requires a multidisciplinary approach with input from a surgeon skilled in hepatobiliary surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19495882     DOI: 10.1245/s10434-009-0538-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  69 in total

1.  Relevance of residual disease after liver resection for incidental gallbladder cancer.

Authors:  Javier C Lendoire; Luis Gil; Fernando Duek; Carlos Quarin; Verónica Garay; Gabriel Raffin; Marcelo Rivaldi; Oks Alejandra; Oscar Imventarza
Journal:  HPB (Oxford)       Date:  2012-06-08       Impact factor: 3.647

Review 2.  Routine histopathology for carcinoma in cholecystectomy specimens not evidence based: a systematic review.

Authors:  Hilko A Swank; Irene M Mulder; Wim C Hop; Marc J van de Vijver; Johan F Lange; Willem A Bemelman
Journal:  Surg Endosc       Date:  2013-07-23       Impact factor: 4.584

3.  Role of cholecystectomy and lymph node dissection in patients with T2 gallbladder cancer.

Authors:  Dong Hyun Kim; Sung Hoon Kim; Gi Hong Choi; Chang Moo Kang; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee
Journal:  World J Surg       Date:  2013-11       Impact factor: 3.352

4.  Expression Analysis of Survivin and XIAP in Gallbladder Cancer: a Case-control Study in Indo-Gangetic Plain.

Authors:  Ruhi Dixit; Mohd Raza; Mohan Kumar; S Basu; V K Shukla
Journal:  J Gastrointest Cancer       Date:  2018-12

5.  Factors that Minimize Curative Resection for Gallbladder Adenocarcinoma: an Analysis of Clinical Decision-Making and Survival.

Authors:  Breanna C Perlmutter; Robert Naples; Asif Hitawala; John McMichael; Pravallika Chadalavada; Vinay Padbidri; Abdo Haddad; Robert Simon; R Matthew Walsh; Toms Augustin
Journal:  J Gastrointest Surg       Date:  2021-02-09       Impact factor: 3.452

6.  Adjuvant Therapy for Gallbladder Cancer: an Analysis of the National Cancer Data Base.

Authors:  Richard S Hoehn; Koffi Wima; Audrey E Ertel; Alexandra Meier; Syed A Ahmad; Shimul A Shah; Daniel E Abbott
Journal:  J Gastrointest Surg       Date:  2015-08-21       Impact factor: 3.452

7.  Surgical procedure determination based on tumor-node-metastasis staging of gallbladder cancer.

Authors:  Xiao-Dong He; Jing-Jing Li; Wei Liu; Qiang Qu; Tao Hong; Xie-Qun Xu; Bing-Lu Li; Ying Wang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

8.  Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium.

Authors:  Georgios Antonios Margonis; Faiz Gani; Stefan Buettner; Neda Amini; Kazunari Sasaki; Nikolaos Andreatos; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2016-08-13       Impact factor: 3.647

9.  Incidental pT2-T3 gallbladder cancer after a cholecystectomy: outcome of staging at 3 months prior to a radical resection.

Authors:  Fabio Ausania; Theodoris Tsirlis; Steven A White; Jeremy J French; Bryon C Jaques; Richard M Charnley; Derek M Manas
Journal:  HPB (Oxford)       Date:  2013-01-07       Impact factor: 3.647

10.  Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer.

Authors:  Faiz Gani; Stefan Buettner; Georgios A Margonis; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2016-05-20       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.